Dopamine deficits and regulation of the cAMP second messenger system in brains of simian immunodeficiency virus-infected rhesus monkeys.
The basal ganglia, structures rich in the neurotransmitter dopamine, are primarily affected during human immunodeficiency virus (HIV) infection. The authors measured levels of dopamine and its metabolites, homovanillic acid and 3,4-dihydroxyphenylacetic acid, in brains of uninfected and simian immunodeficiency virus (SIV)-infected rhesus monkeys during the asymptomatic stage of the infection. Moreover, the authors investigated changes in cyclic adenosine monophosphate (cAMP) and cAMP response element-binding protein (CREB), two factors involved in the signaling pathway of dopamine. The brain regions examined were the nucleus accumbens and the corpus amygdaloideum, which are limbic structures of the basal ganglia that are involved in the pathophysiology of psychiatric disorders and substance abuse. Dopamine content was reduced in both regions of SIV-infected monkeys compared to uninfected animals. Moreover, dopamine deficits were associated with a decrease in expression of total CREB. Intracellular concentrations of cAMP were decreased in nucleus accumbens and remained unchanged in corpus amygdaloideum of SIV-infected macaques. Changes in dopamine signaling were not related to pathology or viral load of the investigated animals. The results suggest that dopamine defects precede neurologic deficits and implicate dysfunction of the dopaminergic system in the etiopathogenesis of HIV dementia. Therefore, affective complications in HIV subjects should not be interpreted only as reactive psychological changes. The alterations in the mesolimbic dopaminergic system during asymptomatic stage of SIV infection implicate a biological background for psychiatric disorders in HIV infection.
Jenuwein
M
M
Clinical Neurochemistry, National Parkinson Foundation Center of Excellence Research Laboratory, Psychiatry and Psychotherapy, University of Würzburg, Wuerzburg, Germany.
Scheller
C
C
Neuen-Jacob
E
E
Sopper
S
S
Tatschner
T
T
ter Meulen
V
V
Riederer
P
P
Koutsilieri
E
E
D015102:3,4-Dihydroxyphenylacetic Acid / Q000032:analysis / Q000378:metabolism; D000818:Animals; D001921:Brain / Q000378:metabolism* / Q000473:pathology / Q000821:virology; D002851:Chromatography, High Pressure Liquid; D000242:Cyclic AMP / Q000378:metabolism*; D017362:Cyclic AMP Response Element-Binding Protein / Q000378:metabolism; D004298:Dopamine / Q000032:analysis / Q000378:metabolism*; D004591:Electrophoresis, Polyacrylamide Gel; D006719:Homovanillic Acid / Q000032:analysis / Q000378:metabolism; D015151:Immunoblotting; D007150:Immunohistochemistry; D008253:Macaca mulatta; D015398:Signal Transduction / Q000502:physiology*; D016097:Simian Acquired Immunodeficiency Syndrome / Q000473:pathology / Q000503:physiopathology*; D015302:Simian Immunodeficiency Virus / Q000502:physiology
D017362:Cyclic AMP Response Element-Binding Protein; D015102:3,4-Dihydroxyphenylacetic Acid; D000242:Cyclic AMP; D004298:Dopamine; D006719:Homovanillic Acid